Graves' Disease Market Positioned for Growth Through 2034, DelveInsight Finds

The Graves' disease market was valued at approximately USD 4.5 billion and is projected to grow at a significant CAGR during the forecast period (2025–2034). DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Graves' disease landscape.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Graves' disease market is increasingly guided by novel immunotherapies targeting underlying autoimmune mechanisms. Antithyroid drugs, particularly methimazole, remain the foundational treatment approach, representing a significant market segment with established efficacy and widespread adoption. However, emerging targeted immunotherapies are revolutionizing the treatment landscape, with monoclonal antibodies and antigen-specific immunotherapies showing promising potential to address treatment-resistant cases and improve long-term remission rates.

DelveInsight's report, "Graves' Disease Market Insights, Epidemiology, and Market Forecast- 2034," provides a comprehensive analysis of the Graves' disease landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Graves' disease market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Graves' disease market outlook, drug uptake, treatment scenario and epidemiology trends, visit Graves' Disease Market Forecast

Some of the Key Facts of the Graves' Disease Market Report:

• Key Graves' Disease Companies: Amgen, Immunovant Sciences, Viridian Therapeutics, argenx, Hoffmann-La Roche, HanAll Biopharma, Samsung Biologics, Sling Therapeutics, Tourmaline Bio, Lassen Therapeutics, Alumis (ACELYRIN), Sanofi, Kissei Pharmaceutical, Regeneron, Horizon Therapeutics, GSK, and others
• Key Graves' Disease Therapies: Methimazole, Propylthiouracil (PTU), Tepezza (teprotumumab-trbw), IMVT-1401 (batoclimab), Veligrotug (VRDN-001), VRDN-003, Efgartigimod PH20 SC, Linsitinib, Lonigutamab, ATX-GD-59, Rituximab, Iscalimab (GSK), K1-70, Tocilizumab, Satralizumab (RG6168/ENSPRYNG), and others
• The Graves' disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Graves' disease pipeline products will significantly revolutionize the Graves' disease market dynamics.

Graves' Disease Overview

Graves' disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSIs) that bind to thyroid-stimulating hormone (TSH) receptors, leading to excessive thyroid hormone production and resulting in hyperthyroidism. It represents the most common cause of hyperthyroidism worldwide and is often associated with extrathyroidal manifestations, most notably Graves' ophthalmopathy (also known as thyroid eye disease or TED), which affects the muscles and fatty tissues behind the eyes, causing proptosis and potential vision complications.

Risk factors include genetic predisposition, female gender, stress, infections, and environmental exposures. Early detection through appropriate thyroid function testing and TSH receptor antibody assessment is critical for timely intervention, and management depends on disease severity and patient-specific factors, ranging from antithyroid medications to surgical interventions and radioactive iodine therapy.

Key Trends in Graves' Disease Therapeutics Market:

• Rising Adoption of Targeted Immunotherapies: Increasing development and utilization of monoclonal antibodies targeting B-cell depletion, TSH receptor signaling, and autoantibody recycling pathways.
• Antigen-Specific Immunotherapy Advancement: Growing interest in peptide-based immunotherapies that restore immune tolerance to thyrotropin receptor without systemic immunosuppression.
• Personalized Treatment Approaches: Enhanced molecular diagnostics and biomarker testing enabling tailored therapeutic strategies based on disease phenotype and autoantibody profiles.
• Pipeline Innovation: Development of next-generation therapies including FcRn inhibitors, IGF-1 receptor antagonists, CD40 pathway inhibitors, and gene therapy approaches for Graves' ophthalmopathy.
• Focus on Graves' Ophthalmopathy: Expanding investment and clinical development in addressing the unmet needs of moderate-to-severe thyroid eye disease, a significant quality-of-life issue.
• Combination Therapy Approaches: Emerging evidence supporting the efficacy of combination treatments for moderate-to-severe Graves' ophthalmopathy, including immunosuppressive agents and surgical interventions.

Graves' Disease Epidemiology

The Graves' disease epidemiology section of the report provides a comprehensive analysis of the disease's prevalence, incidence, and patient demographics. It includes age- and gender-specific distribution, regional and global trends, and data on disease manifestations such as Graves' ophthalmopathy. The report also highlights risk factors, disease burden, and projections for future trends, helping stakeholders understand the scope of Graves' disease and plan targeted interventions, research, and treatment strategies.

Graves' disease represents the most common cause of hyperthyroidism in the United States, representing more than 70% of the total Graves' Disease market across 7MM. The incidence of Graves' disease demonstrated notable gender disparity, with females experiencing significant more incidence compared to males. The disease commonly presents between 30 and 50 years of age, though it can affect individuals of any age.

Graves' Disease Epidemiology Segmentation:

The Graves' disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalent Cases of Graves’ Disease
• Total Diagnosed Prevalent Cases of Graves’ Disease
• Gender-specific Cases of Graves’ Disease
• Graves’ Disease Cases by Manifestations

To understand which factors are driving Graves' disease epidemiology trends, visit: Graves' Disease Epidemiology Forecast

Recent Developments in the Graves' Disease Treatment Landscape:

• In April 2025, Merida Biosciences emerged from stealth with $121 million in Series A financing from Third Rock Ventures to advance a lead antibody-like program targeting Graves' disease and other autoimmune conditions.
• In May 2025, Viridian Therapeutics received FDA Breakthrough Therapy Designation for veligrotug (VRDN-001), an anti-IGF-1R candidate, for thyroid eye disease (TED) associated with Graves' disease.​
• In May 2025, Amgen announced MHRA approval of TEPEZZA (teprotumumab) in the UK for moderate-to-severe TED in adult patients, marking the first specific authorization.
• In January 2025, Sanofi announced the initiation of a Phase II clinical trial for its novel biologic therapy targeting thyroid-stimulating immunoglobulins (TSI) in patients with Graves' disease. This initiative represents a significant milestone in the advancement of monoclonal antibody-based therapies for autoimmune thyroid disorders. By directly neutralizing TSIs, the therapy aims to prevent hyperthyroid flares and minimize relapse rates, offering a targeted treatment alternative to standard antithyroid medications and surgery.
• In January 2025, Sling Therapeutics, Inc., has announced topline efficacy and safety results from the Phase 2b/3 LIDS trial evaluating linsitinib in patients with active, moderate to severe TED. Linsitinib, the company’s lead oral small molecule candidate taken twice daily, targets the well-established IGF-1R pathway. It has demonstrated a favorable safety profile, having been tested in over 900 patients across 15 clinical trials for various conditions.
• In December 2024, Viridian Therapeutics, Inc. (NASDAQ: VRDN) has announced positive topline results from its Phase 3 THRIVE-2 clinical trial. The study evaluated veligrotug (veli), an intravenously administered anti-IGF-1R antibody, in patients with chronic thyroid eye disease.

Graves' Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Graves' disease market or expected to get launched during the study period. The analysis covers Graves' disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Graves' disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Graves' Disease Therapies and Key Companies

• Teprotumumab (Tepezza): Amgen
• Batoclimab (IMVT-1401): Immunovant Sciences / HanAll Biopharma / Samsung Biologics
• Veligrotug (VRDN-001): Viridian Therapeutics / Kissei Pharmaceutical
• VRDN-003: Viridian Therapeutics / Kissei Pharmaceutical
• Efgartigimod PH20 SC: argenx
• Linsitinib: Sling Therapeutics
• Lonigutamab: Kissei Pharmaceutical
• ATX-GD-59: Apeiron Therapeutics
• Rituximab: Hoffmann-La Roche / Genentech
• Iscalimab: GSK
• Tocilizumab: Hoffmann-La Roche
• Satralizumab (RG6168/ENSPRYNG): Hoffmann-La Roche
• KRIYA-586 (Gene Therapy): Kriya Therapeutics
• Pacibekitug (TOUR006): Tourmaline Bio
• LASN01: Lassen Therapeutics, and others.

To know more about Graves' disease companies working in the treatment market, visit: Graves' Disease Clinical Trials and Therapeutic Assessment

Graves' Disease Market Drivers

• Increasing prevalence of Graves' disease and enhanced disease awareness globally, driving demand for effective therapies
• Growth of targeted immunotherapies and monoclonal antibodies for both Graves' hyperthyroidism and associated ophthalmopathy
• Advancements in diagnostic tools and biomarker testing enabling earlier detection and personalized treatment strategies
• Rising healthcare expenditure and government initiatives supporting autoimmune disease management
• Significant unmet medical need in treatment-resistant Graves' disease and moderate-to-severe ophthalmopathy
• Development of novel immunotherapies offering disease-modifying potential and improved safety profiles compared to conventional treatments

Graves' Disease Market Barriers

• High cost of novel immunotherapies limiting patient access and adoption, particularly in emerging markets
• Lengthy clinical trial designs and regulatory approval processes delaying market entry of new therapies
• Limited awareness and accessibility of advanced treatment options in resource-limited regions
• Side effects and safety concerns associated with advanced immunotherapies requiring careful patient monitoring
• Preference for established first-line antithyroid medications due to long-standing clinical experience and lower cost
• Variability in patient response due to genetic and environmental factors affecting treatment efficacy and outcome predictability

Scope of the Graves' Disease Market Report

• Study Period: 2025–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Graves' Disease Companies: Amgen, Immunovant Sciences, Viridian Therapeutics, argenx, Hoffmann-La Roche, HanAll Biopharma, Samsung Biologics, Sling Therapeutics, Tourmaline Bio, Lassen Therapeutics, Alumis (ACELYRIN), Sanofi, Kissei Pharmaceutical, Regeneron, Horizon Therapeutics (now Amgen), GSK, Apeiron Therapeutics, Kriya Therapeutics, and others
• Key Graves' Disease Therapies: Methimazole, Propylthiouracil (PTU), Teprotumumab (Tepezza), IMVT-1401 (batoclimab), Veligrotug (VRDN-001), VRDN-003, Efgartigimod PH20 SC, Linsitinib, Lonigutamab, ATX-GD-59, Rituximab, Iscalimab, K1-70, Tocilizumab, Satralizumab (RG6168/ENSPRYNG), KRIYA-586, Pacibekitug (TOUR006), LASN01, and others
• Graves' Disease Therapeutic Assessment: Graves' disease current marketed and Graves' disease emerging therapies
• Graves' Disease Market Dynamics: Graves' disease market drivers and Graves' disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Graves' Disease Unmet Needs, KOL's views, Analyst's views, Graves' Disease Market Access and Reimbursement

Discover More About Therapies Set to Grab Major Graves' Disease Market Share. Visit: Graves' Disease Treatment Market